Which company produces trifluridine and tipiracil (Lansifer)?

Trifluridine and tipiracil (Lonsurf), manufactured by Taiho Pharmaceutical Co (Taiho Oncology Co., Ltd.), are a combination of thymidine phosphorylase inhibitors and nucleoside metabolism inhibitors used to treat colorectal cancer and adenocarcinoma of the stomach or gastroesophageal junction. Trifluridine and tipiracil contain two ingredients that work synergistically to treat cancer, trifluridine and tipiracil. After uptake by cancer cells, trifluridine is integrated into DNA, interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil increases trifluridine exposure by inhibiting the metabolism of trifluridine via thymidine phosphorylase.

Trifluridine and tipiracil are approved for the treatment of adult patients who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (an anti-VEGF biologic therapy). Type, patients with metastatic colorectal cancer who have received anti-EGFR therapy); or patients with metastatic gastric or gastroesophageal junction adenocarcinoma who have received at least two prior chemotherapy (including fluoropyrimidine, platinum, taxane, or irinotecan), as well as appropriate HER2/neu-targeted therapy. Trifluridine tipiracil is available in tablet form, and the instructions direct patients to take it orally twice daily with food on days 1-5 and 8-12 of each 28-day cycle.

Common adverse reactions of trifluridine and tipiracil when used as a single agent include neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia; warnings and precautions associated with it include severe myelosuppression and embryo-fetal toxicity. Therefore, if patients need to use this drug for treatment, they must use it under the guidance of a doctor.